Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is medulloblastoma?
Medulloblastoma is a type of brain tumor that begins in the cerebellum, the part of the brain at the back of the head that controls balance and coordination. It is the most common cancerous brain tumor in children, though it can occasionally occur in adults. Because it sits near the fluid-filled spaces of the brain, medulloblastoma can block the normal flow of cerebrospinal fluid, causing pressure to build up — leading to headaches (often worse in the morning), nausea and vomiting, and problems with balance and walking. A defining feature is that medulloblastoma can spread through the cerebrospinal fluid to coat the surface of the brain and the spinal cord, which is why treatment must address the entire brain and spine, not just the original tumor. Doctors now recognize that medulloblastoma is not one disease but several molecular subgroups, each with a different biology and outlook, and this knowledge increasingly guides how intensively each child is treated. Despite being aggressive, medulloblastoma is one of the more curable brain tumors, especially when caught and treated promptly. Treatment is a coordinated effort: surgery to remove as much tumor as safely possible, radiation to the whole brain and spine plus a focused boost to the tumor area, and chemotherapy. Because most patients are children whose brains and bodies are still developing, a central goal is to cure the cancer while protecting long-term thinking, growth, and quality of life.
The main types
Doctors group medulloblastoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| WNT-activated medulloblastoma | A subgroup with an excellent outlook; because it responds so well, doctors are studying whether treatment can be safely reduced to lower long-term side effects. |
| SHH-activated medulloblastoma | Driven by the sonic hedgehog pathway; common in infants and adults, with an outlook that varies and treatment tailored to age and other tumor features. |
| Group 3 medulloblastoma | Tends to be more aggressive and more likely to spread, often requiring intensive treatment; a focus of research into better therapies. |
| Group 4 medulloblastoma | The most common subgroup, with an intermediate outlook; treatment is guided by age, spread, and how much tumor was removed. |
Staging, in plain terms
Medulloblastoma is not staged with the usual TNM numbers used for many adult cancers. Instead, doctors sort it into risk groups that determine how intensive treatment should be. Several factors go into this. The first is whether the tumor has spread through the cerebrospinal fluid to the surface of the brain or spine, which is checked with an MRI of the whole brain and spine and a sample of the spinal fluid. The second is how much of the tumor the surgeon was able to remove. The third is the child's age, because very young children are especially vulnerable to the long-term effects of radiation, so treatment is adjusted to protect the developing brain. Increasingly, the molecular subgroup — WNT, SHH, Group 3, or Group 4 — is also factored in, because each behaves differently. Tumors that have not spread and were largely removed, in a child old enough for standard radiation, are generally classified as average-risk, while those that have spread, could not be fully removed, or have higher-risk biology are classified as high-risk and treated more intensively. This risk-based approach lets the team match the strength of treatment to each child's tumor.
| Risk grouping (average-risk vs high-risk) using age, spread, surgery, and molecular subgroup — not TNM | What it generally means |
|---|---|
| Average-risk | Tumor largely removed with little or no leftover, no spread through the spinal fluid, in a child old enough for standard radiation; treated with surgery, standard-dose craniospinal radiation with a boost, and chemotherapy, with high cure rates. |
| High-risk | Tumor that has spread through the spinal fluid, could not be fully removed, or has higher-risk biology; treated more intensively with higher-dose craniospinal radiation and chemotherapy. |
| Infant / very young child | In children too young for standard brain radiation, treatment leans on surgery and chemotherapy to delay or avoid whole-brain radiation, protecting the developing brain, with focused radiation used selectively. |
The standard of care
Medulloblastoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery
An operation removes as much of the tumor as can be done safely and relieves pressure on the brain; how completely the tumor is removed influences the rest of the plan.
Craniospinal radiation with a tumor boost
Because the tumor can seed the entire brain and spine, radiation treats the whole brain and spinal cord at a lower dose, then adds a focused higher-dose boost to the original tumor area.
Chemotherapy
Chemotherapy given during and after radiation helps cure the cancer and, in average-risk patients, allows a lower radiation dose; in infants it can delay or reduce the need for radiation.
Proton therapy when available
Proton beams can deliver the needed dose to the brain and spine while sparing the heart, lungs, and other developing organs from unnecessary radiation, reducing long-term side effects in children.
Survivorship and rehabilitation
Long-term follow-up supports thinking and learning, hormones and growth, hearing, and emotional health, with rehabilitation and school support to help children thrive after treatment.
How radiation treatment works
Radiation therapy uses focused high-energy beams to damage the DNA inside cancer cells so they can no longer grow and divide. Medulloblastoma is especially sensitive to radiation, which is one reason it is so curable, but treating it well requires addressing a particular challenge: the tumor can shed cells into the cerebrospinal fluid that bathes the brain and spinal cord, so those cells can travel and settle far from where the tumor started. For this reason the standard radiation approach is craniospinal irradiation — treating the entire brain and spinal cord at a lower dose to destroy any wandering cells — followed by a focused higher-dose boost to the original tumor site. Because most patients are children whose brains, spines, hearts, and bodies are still developing, protecting healthy tissue is just as important as treating the cancer. Modern planning with intensity-modulated radiation and, where available, proton therapy makes this possible. Protons are particularly valuable here: a proton beam deposits its energy and then stops, so when the spine is treated the radiation does not continue forward into the heart, lungs, and abdomen, and when the tumor area is boosted, nearby healthy brain is spared. For average-risk patients, combining radiation with chemotherapy has allowed doctors to lower the radiation dose to the whole brain and spine while keeping cure rates high — an important advance for reducing effects on learning, growth, and hormones. In the youngest children, teams may delay or limit radiation, leaning on chemotherapy first. Your child's radiation oncologist designs the plan to cure the cancer while protecting long-term development as much as possible.
The main ways radiation is delivered for medulloblastoma:
Craniospinal irradiation (CSI)
Radiation is delivered to the entire brain and spinal cord to destroy tumor cells that may have spread through the cerebrospinal fluid, the foundation of curative treatment for most patients.
Tumor-bed boost (IMRT or focused beams)
After whole brain-and-spine treatment, a higher dose is focused precisely on the area where the tumor was, sparing surrounding healthy brain.
Proton therapy
Proton beams stop at a controlled depth, so when treating the spine the dose does not pass through to the heart, lungs, and abdomen, and when boosting the tumor it spares nearby brain — especially valuable in growing children.
Reduced-dose radiation in favorable cases
For average-risk and certain favorable-biology tumors, a lower craniospinal dose combined with chemotherapy maintains high cure rates while lessening long-term effects on the developing brain.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Proton craniospinal radiation lowers late effects: Studies found that treating the brain and spine with proton therapy spares the heart, lungs, thyroid, and abdominal organs compared with conventional radiation, reducing long-term side effects while maintaining excellent tumor control in children.[1]
Pediatric proton CSI outcomes
Molecular subgroups guide treatment intensity: Research established that medulloblastoma's molecular subgroups — WNT, SHH, Group 3, and Group 4 — carry very different outlooks, and trials are using this biology to safely reduce treatment for favorable tumors and intensify it for aggressive ones.[2]
Medulloblastoma molecular classification studies
Reduced-dose radiation with chemotherapy in average-risk disease: Clinical trials showed that combining a lower craniospinal radiation dose with chemotherapy preserves high cure rates in average-risk children while lessening the impact on thinking and growth.[3]
Average-risk medulloblastoma cooperative trials
Common questions
Why does radiation treat the whole brain and spine, not just the tumor? Medulloblastoma can release cells into the cerebrospinal fluid that flows around the brain and spinal cord, so those cells can travel and settle elsewhere. Treating the entire brain and spine destroys any hidden cells, and then a focused boost adds extra dose to where the tumor began. This combination is what makes the cancer so curable.
Is proton therapy better for children with medulloblastoma? Protons can deliver the needed dose to the brain and spine while stopping before they reach the heart, lungs, and abdominal organs, which spares developing tissue and tends to reduce long-term side effects. It is especially valued in children, though tumor control is excellent with both proton and modern conventional radiation.
Can treatment be made gentler for favorable tumors? Yes. For average-risk and favorable-biology tumors, combining a lower craniospinal radiation dose with chemotherapy keeps cure rates high while lessening effects on learning and growth. Doctors increasingly use the tumor's molecular subgroup to decide how much treatment is needed.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.